{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:28:13Z","timestamp":1790263693531,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic risk factors in primary biliary cholangitis (PBC) have not been well described in China. Additionally, it is unclear whether these factors have an impact on the prognosis of PBC patients. Therefore, this study aimed to investigate the prevalence of main metabolic risk factors in PBC, and to evaluate their prognostic values for liver-related outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cohort of 789 PBC patients was retrospectively studied between July 2008 and September 2019 by investigating the main metabolic risk factors and analyzing liver-related outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At presentation, 271 (34.3%) patients had concomitant hyperlipidemia, 126 (16.0%) had hypertension, 94 (11.9%) had type 2 diabetes mellitus (T2DM), and 17 (2.2%) had nonalcoholic fatty liver disease (NAFLD). Hyperlipidemia was found to be associated with the lower risk of liver-related death [<jats:italic>P<\/jats:italic>&amp;lt;0.0001, hazard ratio (HR): 0.397, 95% confidence interval (CI): 0.268\u20130.588] and adverse outcomes (<jats:italic>P<\/jats:italic>&amp;lt;0.0001, HR: 0.487, 95% CI:0.367\u20130.646), while hypertension was noted as a risk factor for liver-related death (<jats:italic>P<\/jats:italic>=0.001, HR: 1.788, 95% CI:1.268\u20132.521) and adverse outcomes (<jats:italic>P<\/jats:italic>=0.014, HR: 1.417, 95% CI:1.074\u20131.869). Moreover, age \u2265 55 years old (<jats:italic>P<\/jats:italic>=0.005) and cirrhosis (<jats:italic>P<\/jats:italic>&amp;lt;0.0001) had superimposition effects on hypertension as a risk factor for liver-related death, while only cirrhosis (<jats:italic>P<\/jats:italic>&amp;lt;0.0001) had an effect on hypertension as a risk factor for adverse outcomes. Additionally, anti-sp100 was associated with adverse outcomes (<jats:italic>P<\/jats:italic>=0.013) in PBC patients with hypertension in univariate Cox regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hyperlipidemia, hypertension, and T2DM were found as main metabolic risk factors in PBC in China. Hyperlipidemia indicated a benign clinical outcome of PBC, while hypertension indicated a poor outcome of PBC. Older age and cirrhosis had superimposition effects on hypertension for liver-related poor outcomes. Anti-sp100 might be associated with adverse outcomes, especially in PBC patients with hypertension.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1142177","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:24:17Z","timestamp":1699547057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Dan-Tong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09984-x","article-title":"Epidemiology and clinical course of primary biliary cholangitis in the Asia-pacific region: a systematic review and meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Hepatol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.1240854","article-title":"Hypercholesterolemia in primary biliary cirrhosis: getting to the heart of the matter","volume":"124","author":"Chauhan","year":"2003","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2013a new world-wide definition. a consensus statement from the international diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabetes Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"International diabetes federation task force on epidemiology and prevention; hational heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; international association for the study of obesity. harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104333","article-title":"Semisynthetic bile acids: a new therapeutic option for metabolic syndrome","volume":"146","author":"Lazarevi\u0107","year":"2019","journal-title":"Pharmacol Res"},{"key":"B13","article-title":"Risk of incident coronary artery disease in patients with primary biliary cirrhosis","volume":"7","author":"Wang","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3760\/cma.j.issn.0253-3758.2020.01.004","article-title":"National guideline for hypertension management in China (2019)","volume":"48","year":"2020","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12685","article-title":"National workshop on fatty liver and alcoholic liver disease, Chinese society of hepatology, Chinese medical association; fatty liver disease expert committee, Chinese medical doctor association. guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)","volume":"20","author":"Fan","year":"2019","journal-title":"J Dig Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i45.7088","article-title":"Chinese Guidelines on the management of liver cirrhosis (abbreviated version)","volume":"26","author":"Xu","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14521","article-title":"Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: a single center follow-up study from China","volume":"34","author":"Chen","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13006","article-title":"The prognosis and management of inactive HBV carriers","volume":"36","author":"Invernizzi","year":"2016","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1661-7","article-title":"Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients","volume":"56","author":"Zhao","year":"2011","journal-title":"Dig Dis Sci"},{"key":"B22","article-title":"Prevalence rate of dyslipidemia, hyperglycemia, hypertension and metabolic syndrome in a large occupational population in Beijing","volume":"31","author":"ZhiYan","year":"2008","journal-title":"Chin J Lab Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840150518","article-title":"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk","volume":"15","author":"Crippin","year":"1992","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis","volume":"55","author":"Allocca","year":"2006","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2013.10.030","article-title":"Cardiovascular risk, lipidemic phenotype and steatosis. a comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology","volume":"232","author":"Loria","year":"2014","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12452","article-title":"Coronary artery disease in primary biliary cirrhosis: a systematic review and meta-analysis of observational studies","volume":"45","author":"Ungprasert","year":"2015","journal-title":"Hepatol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130409","article-title":"High cholestanol and low campesterol-to-sitosterol ratio in serum of patients with primary biliary cirrhosis before liver transplantation","volume":"13","author":"Nikkil\u00e4","year":"1991","journal-title":"Hepatology"},{"key":"B28","first-page":"89","article-title":"Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics","volume":"21","author":"Gylling","year":"1995","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11906-019-0964-5","article-title":"Hypertension as a metabolic disorder and the novel role of the gut","volume":"21","author":"Tanaka","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)90396-x","article-title":"Reduced central blood volume in cirrhosis","volume":"97","author":"Henriksen","year":"1989","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00521.2002","article-title":"Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender","volume":"284","author":"M\u00f8ller","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.280.4.G584","article-title":"Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index","volume":"280","author":"Henriksen","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260506","article-title":"Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis","volume":"26","author":"Z\u00fcchner","year":"1997","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.03.020","article-title":"Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis","volume":"413","author":"Mytilinaiou","year":"2012","journal-title":"Clin Chim Acta"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","article-title":"Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: national cross sectional study","volume":"369","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13115","article-title":"Diabetes mellitus in patients with cirrhosis: clinical implications and management","volume":"36","author":"Elkrief","year":"2016","journal-title":"Liver Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001782","article-title":"The impact of primary biliary cholangitis on non-alcoholic fatty liver disease","volume":"33","author":"Iluz-Freundlich","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1098076","article-title":"Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: a real-world retrospective study of 537 patients in China","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-013-0136-3","article-title":"Randomized, vitamin e-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose","volume":"34","author":"Han","year":"2014","journal-title":"Clin Drug Investig"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Wah Kheong","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3760\/cma.j.issn.1007-3418.2018.03.008","article-title":"Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update","volume":"26","year":"2018","journal-title":"Zhonghua Gan Zang Bing Za Zhi"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1142177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:24:27Z","timestamp":1699547067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1142177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":46,"alternative-id":["10.3389\/fendo.2023.1142177"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1142177","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"article-number":"1142177"}}